Gastrointestinal Stromal Tumors
"Gastrointestinal Stromal Tumors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).
Descriptor ID |
D046152
|
MeSH Number(s) |
C04.557.450.565.370 C06.301.371.308 C06.405.249.308
|
Concept/Terms |
Gastrointestinal Stromal Tumors- Gastrointestinal Stromal Tumors
- Stromal Tumor, Gastrointestinal
- Stromal Tumors, Gastrointestinal
- Tumor, Gastrointestinal Stromal
- Tumors, Gastrointestinal Stromal
- Gastrointestinal Stromal Neoplasms
- Neoplasm, Gastrointestinal Stromal
- Neoplasms, Gastrointestinal Stromal
- Stromal Neoplasm, Gastrointestinal
- Stromal Neoplasms, Gastrointestinal
- Gastrointestinal Stromal Tumor
- Gastrointestinal Stromal Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Gastrointestinal Stromal Tumors".
Below are MeSH descriptors whose meaning is more specific than "Gastrointestinal Stromal Tumors".
This graph shows the total number of publications written about "Gastrointestinal Stromal Tumors" by people in this website by year, and whether "Gastrointestinal Stromal Tumors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 1 | 0 | 1 | 2006 | 1 | 0 | 1 | 2008 | 1 | 0 | 1 | 2009 | 1 | 0 | 1 | 2010 | 1 | 0 | 1 | 2011 | 1 | 0 | 1 | 2016 | 3 | 0 | 3 | 2017 | 1 | 0 | 1 | 2020 | 5 | 1 | 6 | 2021 | 10 | 0 | 10 | 2022 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Gastrointestinal Stromal Tumors" by people in Profiles.
-
Vincenzi B, Napolitano A, Fiocco M, Mir O, Rutkowski P, Blay JY, Reichardt P, Joensuu H, Fumagalli E, Gennatas S, Hindi N, Nannini M, Spalato Ceruso M, Italiano A, Grignani G, Brunello A, Gasperoni S, De Pas T, Badalamenti G, Pantaleo MA, van Houdt WJ, IJzerman NS, Steeghs N, Gelderblom H, Desar IME, Falkenhorst J, Silletta M, Sbaraglia M, Tonini G, Martin-Broto J, Hohenberger P, Le Cesne A, Jones RL, Dei Tos AP, Gronchi A, Bauer S, Casali PG. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clin Cancer Res. 2022 04 14; 28(8):1672-1679.
-
Napolitano A, Thway K, Smith MJ, Huang PH, Jones RL. KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment. Chemotherapy. 2022; 67(2):81-90.
-
van Houdt WJ, IJzerman NS, Marjolein Schrijver A, Huis In 't Veld E, Thway K, Jones RL, Fotiadis N, Hayes AJ, Bruining A, Zavrakidis I, van Coevorden F, Steeghs N, Mathijssen RHJ, Strauss DC, Smith MJF. Oncological Outcome After Diagnostic Biopsies in Gastrointestinal Stromal Tumors: A Retrospective Cohort Study. Ann Surg. 2021 12 01; 274(6):e1093-e1098.
-
Bauer S, Heinrich MC, George S, Zalcberg JR, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Su Y, Ruiz-Soto R, Blay JY, von Mehren M, Schöffski P. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clin Cancer Res. 2021 12 01; 27(23):6333-6342.
-
Zalcberg JR, Heinrich MC, George S, Bauer S, Schöffski P, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Somaiah N, Meade J, Reichert V, Shi K, Sherman ML, Ruiz-Soto R, von Mehren M, Blay JY. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. Oncologist. 2021 11; 26(11):e2053-e2060.
-
George S, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Razak AA, Gordon MS, Somaiah N, Jennings J, Meade J, Shi K, Su Y, Ruiz-Soto R, Janku F. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer. 2021 09; 155:236-244.
-
Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, Patel S, Zhou Y, von Mehren M, Hohenberger P, Villalobos V, Brahmi M, Tap WD, Trent J, Pantaleo MA, Schöffski P, He K, Hew P, Newberry K, Roche M, Heinrich MC, Bauer S. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
-
Napolitano A, Ostler AE, Jones RL, Huang PH. Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas. Cells. 2021 06 17; 10(6).
-
Mohammadi M, IJzerman NS, Hohenberger P, Rutkowski P, Jones RL, Martin-Broto J, Gronchi A, Schöffski P, Vassos N, Farag S, Baia M, Oosten AW, Steeghs N, Desar IME, Reyners AKL, van Sandick JW, Bastiaannet E, Gelderblom H, Schrage Y. Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. Eur J Surg Oncol. 2021 08; 47(8):2173-2181.
-
George S, Jones RL, Bauer S, Kang YK, Schöffski P, Eskens F, Mir O, Cassier PA, Serrano C, Tap WD, Trent J, Rutkowski P, Patel S, Chawla SP, Meiri E, Gordon M, Zhou T, Roche M, Heinrich MC, von Mehren M. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist. 2021 04; 26(4):e639-e649.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|